Lucid Diagnostics Prices $18M Underwritten Offering at $1.00/Share to Address Capital Needs

summarizeSummary

Lucid Diagnostics priced an $18 million underwritten public offering of 18 million common shares at $1.00 each, securing crucial funding for working capital and general corporate purposes, with significant institutional investor support.

check_boxKey Events

• Underwritten Offering Priced

  Lucid Diagnostics priced an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share.

• Gross Proceeds of $18 Million

  The offering is expected to generate gross proceeds of $18,000,000 before deducting underwriting discounts and expenses.

• Institutional Investor Anchors Offering

  The offering is anchored by a $15 million investment from a fundamental institutional investor, with support from a large existing shareholder.

• Funds for Working Capital

  Net proceeds from the offering will be used for working capital and general corporate purposes, addressing the company's previously disclosed going concern warning.

auto_awesomeAnalysis

Lucid Diagnostics Inc. has priced an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share, generating gross proceeds of $18 million. This offering, made under an existing shelf registration statement, finalizes the terms of a significant capital raise. The pricing represents a discount of approximately 12.16% compared to the current stock price of $1.1384. The company previously disclosed a going concern warning in its most recent 10-K, making this capital infusion critical for its operations and to extend its financial runway. A notable positive is the $15 million investment from a fundamental institutional investor, signaling confidence in the company's future despite the dilutive nature of the offering. The issuance of 18 million new shares represents approximately 10.6% dilution to existing shareholders.